Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Open in API
Filings indexed 208 across all filing types
Latest filing 2023-08-17 Regulatory Filings
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a request form for shareholders to elect to receive annual or interim financial statements and MD&A documents. It does not contain any actual financial data, analysis, or report content. It is a communication related to continuous disclosure obligations and provides instructions for shareholders to request reports. The document length is short (1383 characters) and it is essentially an announcement or request form rather than a report itself. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-08-17 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for the Annual Meeting of Thiogenesis Therapeutics, Corp. It includes instructions for voting on resolutions such as re-appointment of auditors and election of directors. It also contains proxy voting guidelines and a request for financial statements. There is no actual financial data or report content included, only proxy solicitation materials and voting instructions. This fits the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2023-08-17 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 90% confidence The document is a confirmation notice from TSX Trust Company regarding the record and meeting dates for the upcoming Annual Meeting of Security Holders of Thiogenesis Therapeutics Corp. It specifies the meeting date, record date, and details about voting and notice distribution. The content is administrative and pertains to the scheduling and notification of the annual meeting rather than the meeting materials themselves or the results. The document is short (1885 characters) and serves as an announcement of meeting logistics rather than substantive meeting content or financial data. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) since it relates to shareholder meeting dates and voting rights, but more precisely it is a notice related to the meeting and voting process. However, since it is a confirmation of notice and meeting dates rather than actual voting results, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about meeting logistics that does not fit other categories exactly.
2023-07-19 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for the three months ended March 31, 2023 and 2022. It contains detailed financial statements including statements of financial position, operations, changes in shareholders' equity, and cash flows. The document references compliance with IAS 34 'Interim Financial Reporting' and includes management's approval date. The length is substantial (15,000 characters), and it contains actual financial data and analysis for a period shorter than a full fiscal year (quarterly). Therefore, this document is a comprehensive interim financial report, not just an announcement or certification. It fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-05-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings by the CEO of Thiogenesis Therapeutics, Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. The document is primarily an officer certification letter and does not contain actual financial data or substantive financial analysis. It references the interim filings but does not include them. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3046 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-05-24 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2, which is a certification of interim filings by the Chief Financial Officer of Thiogenesis Therapeutics, Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. The document is primarily an officer certification letter and does not contain actual financial data or the interim report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is 3004 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-05-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.